Key result
Newly diagnosed cancer is linked to ~62% hypertension prevalence, significantly exceeding the general population.
Why the study?
Arterial hypertension is a major cardiovascular risk factor associated with increased cardiotoxicity risk in cancer patients, but its prevalence in newly diagnosed cancer versus the general population required determination.
Does newly diagnosed cancer increase the prevalence of hypertension compared to the general population?
Observational (n=1,523)
Yes
Does newly diagnosed cancer increase the prevalence of hypertension compared to the general population?
Absolute Event Rate: 62.3% vs 42.7%
The high prevalence of hypertension in newly diagnosed cancer patients highlights the importance of routine cardiovascular risk assessment and blood pressure monitoring before initiating oncological therapy.
Elevated hypertension rates at colorectal/lung cancer diagnosis; leaves open whether malignancy independently contributes versus shared risks.
BACKGROUND: Arterial hypertension is a major cardiovascular risk factor (CVRF) associated with increased risk of cardiotoxicity in cancer patients. AIMS: The aim of this study was to determine the prevalence of hypertension in patients with newly diagnosed cancer and compare it with the prevalence in the general population. METHODS: Data were derived from the CONNECT-POL registry, the largest prospective Polish study assessing the burden of cardiovascular problems among cancer patients. Inclusion criteria were adult age and newly diagnosed breast, lung, colorectal, or prostate cancer. The occurrence of CVRF and cardiovascular diseases were recorded during a cardiology consultation. RESULTS: Between October 2023 and February 2025 in 11 centers 1523 patients were enrolled - 951 women, 572 men, at median age 67 (interquartile range 16) years. The most frequent CVRF was arterial hypertension, present in 949 patients (62.3%). The prevalence of hypertension reached 79.1% in colorectal, 75.1% in prostate, 69.4% in lung, and 50.1% in breast cancer. In multivariable analysis, hypertension was independently associated with age, body weight, dyslipidemia, diabetes, obesity and colon cancer compared to other cancer types. After age standardization to the structure of the WOBASZ II study, the prevalence of hypertension was higher among patients with colorectal (P = 0.045) and lung (P = 0.002) cancer compared with general population. CONCLUSIONS: The prevalence of hypertension in cancer patients is very high compared to the general population and varies by cancer type, being highest in colorectal cancer and lowest in breast cancer patients. These results highlight the importance of routine blood pressure monitoring and encouraging home blood pressure monitoring in patients scheduled for oncological therapy.
No takes yet. Share an insight, caveat, or question.
Styczkiewicz et al. (2026) conducted an observational in Newly diagnosed breast, lung, colorectal, or prostate cancer (n=1,523). Newly diagnosed cancer vs. General population was evaluated on Prevalence of hypertension. Arterial hypertension was present in 62.3% of patients with newly diagnosed cancer, with age-standardized prevalence significantly higher in colorectal (P=0.045) and lung (P=0.002) cancer compared to the general population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: